+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5896331
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Biosimulation Market grew from USD 3.81 billion in 2023 to USD 4.40 billion in 2024. It is expected to continue growing at a CAGR of 14.55%, reaching USD 9.87 billion by 2030.

By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.

Regional Insights

The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Biosimulation Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing emphasis on research of personalized medicine
  • Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines

Market Restraints

  • Upscaled prices involved in installations and technique developments for biosimulation

Market Opportunities

  • Ongoing advancements in simulation solutions to enhance the novel biologic therapies
  • Rising investments for drug developments and drug testings

Market Challenges

  • Lack of awareness coupled with complexities for creating accurate outcomes

Market Segmentation Analysis

  • Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
  • Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
  • End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
  • Application: Increasing application of biosimulation for drug development

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biosimulation Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients

Certara Inc. has partnered with the Drugs for Neglected Diseases Initiative (DNDi) to utilize Certara's data science platform, Pinnacle 21 Enterprise (P21E). This collaboration aims to enhance data flow and expedite the analysis and submission of new treatments for health authority review.

Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development

Certara Inc. launched Version 8.4 of its Phoenix biosimulation software for drug development. This new version features improved usability and scalability in heterogeneous computing environments and enable users to create more efficient workflows by utilizing the power of high-performance computing.

Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery

Certara Inc. expanded the horizons of AI in drug discovery by introducing artificial intelligence (AI) capabilities and data fabric connectivity to its clinical trials outcome analytics platform, CODEX. The Codex platform has been enhanced with additional capabilities, allowing users to accurately simulate their experiments and quickly generate unprecedented datasets for further analysis.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biosimulation Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systèmes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offering- Services

  • Contract Services
  • In-House Services

Software

  • Molecular Modeling & Simulation Software
  • PBPK Modeling & Simulation Software
  • PK/PD Modeling & Simulation Software
  • Toxicity Prediction Software
  • Trial Design Software

Delivery Model

  • Ownership Models
  • Subscription Models

End-User

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Authorities
  • Research Institutes
  • Application

Drug Development

  • Clinical Trials

Preclinical Testing

  • ADME/Tox
  • PK/PD

Drug Discovery

  • Lead Identification & Optimization
  • Target Identification & Validation

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing emphasis on research of personalized medicine
5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
5.1.2. Restraints
5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
5.1.3.2. Rising investments for drug developments and drug testings
5.1.4. Challenges
5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
5.2. Market Segmentation Analysis
5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
5.2.4. Application: Increasing application of biosimulation for drug development
5.3. Market Trend Analysis
5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter’s Five Forces Analysis
5.6.1. Threat of New Entrants
5.6.2. Threat of Substitutes
5.6.3. Bargaining Power of Customers
5.6.4. Bargaining Power of Suppliers
5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
6. Biosimulation Market, by Offering
6.1. Introduction
6.2. Services
6.3. Software
7. Biosimulation Market, by Delivery Model
7.1. Introduction
7.2. Ownership Models
7.3. Subscription Models
8. Biosimulation Market, by End-User
8.1. Introduction
8.2. Contract Research Organizations
8.3. Pharmaceutical & Biotechnology Companies
8.4. Regulatory Authorities
8.5. Research Institutes
9. Biosimulation Market, by Application
9.1. Introduction
9.2. Drug Development
9.3. Drug Discovery
10. Americas Biosimulation Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biosimulation Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biosimulation Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
13.3.2. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
13.3.3. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
13.3.4. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
13.3.5. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
13.3.6. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
13.3.7. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
13.3.8. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
13.3.9. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
13.3.10. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
13.3.11. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
13.3.12. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
13.3.13. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
13.3.14. Resolution Medical Acquires LifeTec Group
13.3.15. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. BIOSIMULATION MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMULATION MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOSIMULATION MARKET DYNAMICS
FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 66. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 67. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 68. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 69. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 70. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 71. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 72. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 73. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 74. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 75. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 76. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 77. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 78. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 79. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 80. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 81. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 82. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 83. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 84. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 85. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 86. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 87. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 88. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 89. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 90. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 91. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 92. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 93. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 94. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 95. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 96. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 97. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 98. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 100. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 102. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 104. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 106. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 108. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 109. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 110. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 111. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 112. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 113. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 114. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 115. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 116. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 117. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 118. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 119. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 120. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 121. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 122. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 123. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 124. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 125. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 126. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 127. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 128. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 129. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 130. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 131. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 132. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 133. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 134. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 135. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 136. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 137. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 138. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 139. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 140. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 141. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 142. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 143. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 144. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 145. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 146. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 147. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 148. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 149. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 150. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 151. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 152. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 153. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 154. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 155. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 156. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 157. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 158. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 159. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 160. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 161. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 162. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 163. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 164. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 165. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 166. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 167. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 168. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 169. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 170. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 171. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 172. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 173. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 174. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 175. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 176. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 177. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 178. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 179. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 180. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 181. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 182. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 184. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 186. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 188. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 190. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 192. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 194. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 196. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 198. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 200. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 202. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 203. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 204. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 205. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 206. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 207. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 208. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 209. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 210. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 211. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 212. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 213. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 214. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 215. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 216. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 217. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 218. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 219. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 220. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 221. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 222. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 223. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 224. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 225. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 226. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 227. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 228. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 229. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 230. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 231. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 234. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 235. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 236. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 237. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 238. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 239. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 240. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 241. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 242. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 243. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 244. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 245. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 246. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 247. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 248. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 249. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 250. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 251. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 252. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 253. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 254. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 255. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 256. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 257. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 258. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 259. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 260. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 261. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 262. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 263. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 264. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 265. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 268. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 269. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 270. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 271. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 272. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 273. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 274. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 275. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 276. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 277. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 278. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 279. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 280. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 281. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 282. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 283. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 284. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 285. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 286. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 287. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 288. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 289. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 290. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 291. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 292. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 293. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 294. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 295. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 296. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 297. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 298. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 299. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 300. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 301. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 302. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 303. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 304. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 305. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 306. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 307. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 308. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 309. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 310. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 311. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 312. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 313. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 314. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 315. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 316. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 317. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 318. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 319. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 320. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 321. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 322. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 323. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 324. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 325. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 326. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 327. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 328. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 329. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 330. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 331. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 332. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 333. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 334. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 335. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 336. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 337. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 338. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 339. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 340. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 341. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 342. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 343. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 344. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 345. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 346. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 347. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 348. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
TABLE 349. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
TABLE 350. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
TABLE 351. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
TABLE 352. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
TABLE 353. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
TABLE 354. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
TABLE 355. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 356. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 357. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 358. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 359. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
TABLE 360. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
TABLE 361. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
TABLE 362. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
TABLE 363. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
TABLE 364. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
TABLE 365. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
TABLE 366. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING,

Companies Mentioned

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Applied BioMath, LLC
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Compugen Ltd.
  • Crystal Pharmatech Co., Ltd.
  • Dassault Systèmes SE
  • Genedata AG
  • Immunetrics Inc
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • Instem PLC
  • Laboratory Corporation of America Holdings
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Rosa & Co LLC
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life.
  • VIRTUALMAN
  • Yokogawa Electric Corporation

Methodology

Loading
LOADING...

Table Information